3111 - 3120 of 7916 Results
Title
Year
- Drug Repurposing: Considerations to Surpass While Re-directing Old Compounds for New Treatments2021RESTRICTEDTitle: Drug Repurposing: Considerations to Surpass While Re-directing Old Compounds for New TreatmentsJournal Name: Archives of Medical ResearchPublisher: Elsevier BVVol: 52Issue #: 3Start Page: 243End Page: 251Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.arcmed.2020.10.021Citation Count: 25
- Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: An individual patient data meta‐analysis2021RESTRICTEDTitle: Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: An individual patient data meta‐analysisJournal Name: CancerPublisher: WileyVol: 127Issue #: 14Start Page: 2409End Page: 2422Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1002/cncr.33516Best OA location URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cncr.33516Citation Count: 75
-
OPENTitle: Evidence forGRNconnecting multiple neurodegenerative diseasesJournal Name: Brain CommunicationsPublisher: Oxford University Press (OUP)Vol: 3Issue #: 2Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1093/braincomms/fcab095Best OA location URL: https://academic.oup.com/braincomms/article-pdf/3/2/fcab095/41728465/fcab095.pdfCitation Count: 29
-
OPENTitle: Fluoxetine for the Symptomatic Treatment of Multiple System Atrophy: The MSA‐FLUO TrialJournal Name: Movement DisordersPublisher: WileyVol: 36Issue #: 7Start Page: 1704End Page: 1711Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1002/mds.28569Best OA location URL: https://repositorio.uca.edu.ar/bitstream/123456789/11645/6/fluoxetine-symptomatic-treatment-atrophy%20%281%29.pdfCitation Count: 19
-
RESTRICTEDTitle: Genetic updates on paroxysmal dyskinesiasJournal Name: Journal of Neural TransmissionPublisher: Springer Science and Business Media LLCVol: 128Issue #: 4Start Page: 447End Page: 471Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1007/s00702-021-02335-xCitation Count: 8
-
OPENTitle: Genome-Wide Association Study Meta-Analysis for Parkinson Disease Motor SubtypesJournal Name: Neurology GeneticsPublisher: Ovid Technologies (Wolters Kluwer Health)Vol: 7Issue #: 2Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-nd, cc-by-nc-ndDOI - Digital Object Identifier: 10.1212/nxg.0000000000000557Best OA location URL: https://ng.neurology.org/content/nng/7/2/e557.full.pdfCitation Count: 34
-
RESTRICTEDTitle: Intersection of immunometabolism and immunosenescence during agingJournal Name: Current Opinion in PharmacologyPublisher: Elsevier BVVol: 57Issue #:Start Page: 107End Page: 116Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.coph.2021.01.003Best OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8481958Citation Count: 21
-
RESTRICTEDTitle: Mindfulness based stress reduction in people with Parkinson's disease and their care partnersJournal Name: Complementary Therapies in Clinical PracticePublisher: Elsevier BVVol: 43Issue #:Start Page: 101377End Page: 101377Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.ctcp.2021.101377Citation Count: 8
-
OPENTitle: Perturbations of cancer cell metabolism by the antidiabetic drug canagliflozinJournal Name: NeoplasiaPublisher: Elsevier BVVol: 23Issue #: 4Start Page: 391End Page: 399Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.neo.2021.02.003Best OA location URL: https://doi.org/10.1016/j.neo.2021.02.003Citation Count: 16
- Regional cerebral cholinergic nerve terminal integrity and cardinal motor features in Parkinson’s disease2021OPENTitle: Regional cerebral cholinergic nerve terminal integrity and cardinal motor features in Parkinson’s diseaseJournal Name: Brain CommunicationsPublisher: Oxford University Press (OUP)Vol: 3Issue #: 2Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1093/braincomms/fcab109Best OA location URL: https://academic.oup.com/braincomms/article-pdf/3/2/fcab109/41723515/fcab109.pdfCitation Count: 27